GEP201606522B - Inhibitors of nedd8-activating enzyme - Google Patents

Inhibitors of nedd8-activating enzyme

Info

Publication number
GEP201606522B
GEP201606522B GEAP201213424A GEAP2012013424A GEP201606522B GE P201606522 B GEP201606522 B GE P201606522B GE AP201213424 A GEAP201213424 A GE AP201213424A GE AP2012013424 A GEAP2012013424 A GE AP2012013424A GE P201606522 B GEP201606522 B GE P201606522B
Authority
GE
Georgia
Prior art keywords
nedd8
inhibitors
activating enzyme
pharmaceu
inden
Prior art date
Application number
GEAP201213424A
Other languages
English (en)
Inventor
Ashley Sue Mccarron
Todd B Sells
Matthew Stirling
Stephen G Stroud
Original Assignee
Millennium Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Millennium Pharm Inc filed Critical Millennium Pharm Inc
Publication of GEP201606522B publication Critical patent/GEP201606522B/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • C07D473/02Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • C07D473/26Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32Nitrogen atom
    • C07D473/34Nitrogen atom attached in position 6, e.g. adenine

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
GEAP201213424A 2011-08-24 2012-08-23 Inhibitors of nedd8-activating enzyme GEP201606522B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161526830P 2011-08-24 2011-08-24

Publications (1)

Publication Number Publication Date
GEP201606522B true GEP201606522B (en) 2016-08-10

Family

ID=47747080

Family Applications (1)

Application Number Title Priority Date Filing Date
GEAP201213424A GEP201606522B (en) 2011-08-24 2012-08-23 Inhibitors of nedd8-activating enzyme

Country Status (29)

Country Link
US (3) US8809356B2 (enExample)
EP (2) EP3323414A1 (enExample)
JP (1) JP6038150B2 (enExample)
KR (1) KR20140054288A (enExample)
CN (1) CN103889988B (enExample)
AR (1) AR087672A1 (enExample)
AU (1) AU2012298813B2 (enExample)
BR (1) BR112014004239A2 (enExample)
CA (1) CA2846231C (enExample)
CL (1) CL2014000441A1 (enExample)
CO (1) CO6900148A2 (enExample)
CR (1) CR20140128A (enExample)
DO (1) DOP2014000037A (enExample)
EA (1) EA031067B1 (enExample)
EC (1) ECSP14013263A (enExample)
GE (1) GEP201606522B (enExample)
HK (1) HK1199252A1 (enExample)
IL (1) IL231069B (enExample)
MA (1) MA35439B1 (enExample)
MX (1) MX2014002015A (enExample)
MY (1) MY166889A (enExample)
PE (1) PE20141146A1 (enExample)
PH (1) PH12014500419A1 (enExample)
SG (2) SG10201601023UA (enExample)
TN (1) TN2014000080A1 (enExample)
TW (1) TWI577667B (enExample)
UA (1) UA114894C2 (enExample)
UY (1) UY34292A (enExample)
WO (1) WO2013028832A2 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8008307B2 (en) 2006-08-08 2011-08-30 Millennium Pharmaceuticals, Inc. Heteroaryl compounds useful as inhibitors of E1 activating enzymes
JP6038150B2 (ja) * 2011-08-24 2016-12-07 ミレニアム ファーマシューティカルズ, インコーポレイテッドMillennium Pharmaceuticals, Inc. Nedd8活性化酵素阻害剤
GEP201706687B (en) 2012-02-17 2017-06-26 Millennium Pharmaceuticals Inc (A Delaware Corporation) Pyrazolopyrimidinyl inhibitors of ubiquitin-activating enzyme
CN104684559A (zh) 2012-08-03 2015-06-03 米伦纽姆医药公司 针对Uba6的吲哚取代的吡咯并嘧啶基抑制剂
EP2764866A1 (en) 2013-02-07 2014-08-13 IP Gesellschaft für Management mbH Inhibitors of nedd8-activating enzyme
JP6378759B2 (ja) * 2013-07-02 2018-08-22 ミレニアム ファーマシューティカルズ, インコーポレイテッドMillennium Pharmaceuticals, Inc. Sumo活性化酵素阻害剤として有用なヘテロアリール化合物
CN103948590A (zh) * 2014-05-22 2014-07-30 中国药科大学 Nedd8激活酶抑制剂及其医药用途
EP3901159A1 (en) * 2014-07-01 2021-10-27 Millennium Pharmaceuticals, Inc. Heteroaryl compounds useful as inhibitors of sumo activating enzyme
WO2017183927A1 (ko) * 2016-04-20 2017-10-26 한국화학연구원 신규한 헤테로고리 화합물, 이의 제조방법 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물
WO2018213258A1 (en) * 2017-05-15 2018-11-22 Millennium Pharmaceuticals, Inc. Treatment of merlin-deficient tumors using nae inhibitors
AU2019265134B2 (en) 2018-05-08 2024-02-29 Nippon Shinyaku Co., Ltd. Azabenzimidazole compounds and pharmaceutical
WO2023025668A1 (en) 2021-08-25 2023-03-02 Asociación Centro De Investigación Cooperativa En Biociencias-Cic Biogune Methods for the generation of stem cell memory t cells for adoptive t cell therapy

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5194446A (en) 1989-06-12 1993-03-16 A. H. Robins Company, Incorporated Compounds having one or more aminosulfaonyloxy radicals useful as pharmaceuticals
AU6500696A (en) 1995-07-28 1997-02-26 Cubist Pharmaceuticals, Inc. Aminoacyl adenylate mimics as novel antimicrobial and antiparasitic agents
WO2004043955A1 (en) 2002-11-13 2004-05-27 Rigel Pharmaceuticals, Inc. Rhodanine derivatives and pharmaceutical compositions containing them
EP1680431A1 (en) 2003-10-17 2006-07-19 Rigel Pharmaceuticals, Inc. Benzothiazole and thiazole'5,5-b!pyridine compositions and their use as ubiquitin ligase inhibitors
EP1758873A1 (en) 2004-06-22 2007-03-07 Rigel Pharmaceuticals, Inc. Ubiquitin ligase inhibitors
HRP20120847T1 (hr) 2005-02-04 2012-11-30 Millennium Pharmaceuticals, Inc. Inhibitori e1 aktivirajuä†ih enzima
CA2639924C (en) 2006-02-02 2017-01-10 Millennium Pharmaceuticals, Inc. Purinyl-and pyrrolo[2,3-d]pyrimidinyl cyclopentyl compounds and their use as inhibitors of e1 activating enzymes
US8008307B2 (en) * 2006-08-08 2011-08-30 Millennium Pharmaceuticals, Inc. Heteroaryl compounds useful as inhibitors of E1 activating enzymes
DE602007009998D1 (de) * 2006-08-08 2010-12-02 Millennium Pharm Inc Heteroarylverbindungen als hemmer der e1-aktivierenden enzyme
SG10201402148SA (en) 2009-05-14 2014-07-30 Millennium Pharm Inc Hydrochloride salt of ((1s,2s,4r)-4-{4-[(1s)-2,3-dihydro-1h-inden-1-ylamino]-7h-pyrrolo [2,3-d]pyrimidin-7-yl}-2-hydroxycyclopentyl)methyl sulfamate
JP6038150B2 (ja) * 2011-08-24 2016-12-07 ミレニアム ファーマシューティカルズ, インコーポレイテッドMillennium Pharmaceuticals, Inc. Nedd8活性化酵素阻害剤
CN104245699B (zh) * 2011-11-03 2017-06-27 米伦纽姆医药公司 Nedd8‑活化酶抑制剂和低甲基化剂的投与

Also Published As

Publication number Publication date
UA114894C2 (uk) 2017-08-28
SG10201601023UA (en) 2016-03-30
CN103889988A (zh) 2014-06-25
US20150011572A1 (en) 2015-01-08
WO2013028832A2 (en) 2013-02-28
EA031067B1 (ru) 2018-11-30
EP3323414A1 (en) 2018-05-23
JP6038150B2 (ja) 2016-12-07
EP2748168A4 (en) 2015-04-22
TWI577667B (zh) 2017-04-11
CL2014000441A1 (es) 2014-09-26
EP2748168A2 (en) 2014-07-02
JP2014524476A (ja) 2014-09-22
HK1199252A1 (en) 2015-06-26
CA2846231A1 (en) 2013-02-28
SG11201400102WA (en) 2014-03-28
PE20141146A1 (es) 2014-09-21
MX2014002015A (es) 2014-03-27
US9850214B2 (en) 2017-12-26
AR087672A1 (es) 2014-04-09
US20130150388A1 (en) 2013-06-13
WO2013028832A3 (en) 2013-05-02
TN2014000080A1 (en) 2015-07-01
TW201313689A (zh) 2013-04-01
DOP2014000037A (es) 2014-04-15
UY34292A (es) 2013-04-05
US8809356B2 (en) 2014-08-19
AU2012298813B2 (en) 2016-07-28
CN103889988B (zh) 2018-05-04
MA35439B1 (fr) 2014-09-01
MY166889A (en) 2018-07-24
KR20140054288A (ko) 2014-05-08
EA201400249A1 (ru) 2014-05-30
AU2012298813A1 (en) 2013-05-02
NZ622220A (en) 2016-04-29
US20180290983A1 (en) 2018-10-11
PH12014500419A1 (en) 2020-06-22
CR20140128A (es) 2014-05-15
IL231069A0 (en) 2014-03-31
CO6900148A2 (es) 2014-03-20
ECSP14013263A (es) 2014-04-30
BR112014004239A2 (pt) 2017-03-21
IL231069B (en) 2018-02-28
CA2846231C (en) 2017-06-20

Similar Documents

Publication Publication Date Title
GEP201606522B (en) Inhibitors of nedd8-activating enzyme
NZ710405A (en) Pyrimidine hydroxy amide compounds as protein deacetylase inhibitors and methods of use thereof
EA201370166A1 (ru) Содержащие диарилацетиленгидразид ингибиторы тирозинкиназы
MX2012002752A (es) Compuestos de heteroarilo como inhibidores de cinasa.
GEP20146102B (en) Compounds and compositions as protein kinase inhibitors
GEP20135919B (en) Benzoic acid (1-phenyl-2-pyridin-4-yl) ethyl esters as phosphodiesterase inhibitors
GEP20146146B (en) Pyrrolopyrimidine compounds as inhibitors of cdk4/6
GEP20125599B (en) Proteasome inhibitors
JO2885B1 (en) Protein kinase inhibitors
EA201000092A1 (ru) Тризамещенные пиримидиновые производные для лечения пролиферативных заболеваний
MX2013013294A (es) Inhibidores de tirosina-cinasas.
SG10201405826RA (en) Inhibitors of influenza viruses replication
MX2009011579A (es) Pirimidinonas como moduladores de caseina cinasa ii (ck2).
MX2012002876A (es) Derivados de dihidropteridinona, proceso para su preparacion y uso farmaceutico.
MX2011011733A (es) Inhiibidores de dihidroorotato deshidrogenasa como compuestos virostaticos.
MX2009006865A (es) Proceso para la preparacion de compuestos 6,6-dimetil-3-aza-bicicl o-[3.1.0]-hexano utilizando intermediario bisulfitico.
GEP20156242B (en) 2-arylimidazole derivatives as pde10a enzyme inhibitors
GEP20186880B (en) 2-amino-3, 5, 5-trifluoro-3, 4, 5, 6-tetrahydropyridines as bace1 inhibitors for treatment of alzheimer's disease
WO2007042786A3 (en) 4 -heteroaryl pyrimidine derivatives and use thereof as protein kinase inhibitors
MX2012015100A (es) Compuestos y composiciones de heteroarilo como inhibidores de cinasa de proteina.
GEP20166481B (en) (crystalline forms of hydrochloride salt of (4a-r, 9a-s)-1-(1h-benzoimidazole-5-carbonyl)-2, 3, 4, 4a, 9, 9a-hexa- hydro-1h-indeno [2, 1-b] pyridine-6-carbonitrile and their use as hsd 1 inhibitors
PH12014500107A1 (en) N- (6- ( (2r,3s) -3,4-dihydroxybutan-2-yloxy) -2- (4 - fluorobenzylthio) pyrimidin- 4 - yl) -3- methylazetidine- 1 - sulfonamide as chemokine receptor modulator
MX2009011059A (es) Aminopirimidinas utiles como inhibidores de cinasas.
NZ586720A (en) Hydroxylated pyrimidyl cyclopentane as akt protein kinase inhibitor
EP4477222A3 (en) Crystalline 4-(5-chloro-2-isopropylaminopyridin-4-yl)-1h-pyrrole-2-carboxylic acid [1-(3-chlorophenyl)-2-hydroxyethyl]amide hydrochloride salt